<DOC>
	<DOCNO>NCT00646386</DOCNO>
	<brief_summary>Multicenter Study Safety Efficacy Human Anti-TNF Monoclonal Antibody Adalimumab Subjects Moderately Severely Active Psoriatic Arthritis</brief_summary>
	<brief_title>Study Safety Efficacy Human Anti-TNF Monoclonal Antibody Adalimumab Subjects With Moderately Severely Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate severe PsA Inadequate response DMARD therapy Corticosteroid stable dose &lt; = 10 mg QD DMARDs must take 3 month stable dose 4 week MTX maximum dose = &lt; = 30 mg/week Active chronic plaque PS document history chronic plaque PS No active skin disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>